Category: Funding Roundup
A Chinese venture capital investor takes a $5.7 million stake in incision-closure device maker ZipLine Medical.
ZipLine Medical said it added a $5.7 million extension to its $4.3 million Series C round, with new investor China Materialia promising to help the company expand sales in the People's Republic.
Stealth-mode startup Sinopsys Surgical reports an $8.3 million funding round for the sinusitis drug-device treatment it's developing.
Stealth-mode startup Sinopsys Surgical said it raised $8.3 million in an equity funding round for the technique it's developing to repurpose the tear duct to drain into the sinuses as a way to relieve chronic sinusitis.
CEO Dr. Harry Ross was a partner with Aweida Venture Partners of Superior, Colo., near to Sinopsys Surgical's Boulder headquarters.
Here's a look at some of the top legal news stories for medical device companies this week: FDA nod triggers $30m milestone for Astute Medical; C2 Therapeutics raises $11.6m in equity funding; Report: Minnesota life science investment closes in on 5-year high; MID Labs lands $51m for eye surgery devices
MID Labs lands a $51 million funding round led by OrbiMed and Frontline BioVentures for its eye surgery devices.
MID Labs Ltd. said today that it raised a $51 million funding round for its eye surgery devices it plans to use to expand in the U.S. and China.
The round, led by OrbiMed and Frontline BioVentures, also included Softbank China Venture Capital, Allen Chao and Sungent BioVenture, according to a press release.
Investment in Minnesota's life sciences sector is on track to reach a 5-year high, according to a report from LifeScience Alley.
C2 Therapeutics raises $11.6 million in the wake of FDA clearance for its esophageal ablation device.
C2 Therapeutics raised $11.6 million in equity funding, according to a recent regulatory filing.
Astute Medical is in line to receive up to $30 million from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test.
Astute Medical said it's in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.